EUCTR2015-002310-72-CZ进行中（未招募）1 期
Open-label, uncontrolled trial to evaluate pharmacokinetics of naloxone in children from 4 to less than 18 years of age with opioid-induced constipation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and female paediatric patients, from 4 years (provided that they are able to swallow the tablet) to less than 18 years of age.
- •-Subjects with malignant or non-malignant pain who are requiring (or are about to require) short-term or long-term treatment with opioids (i.e. start of opioid treatment on the day of screening at the latest).
- •-In the investigator’s judgement, subjects must be either newly diagnosed with OIC or subjects must have a history of OIC treated with laxatives or are expected to develop constipation after initiation of opioid treatment.
- •-Female subjects of childbearing potential (postmenarchal) must have a negative urine pregnancy test at screening. Females of childbearing potential must either not be sexually active or be using an adequate birth control method throughout the duration of the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 72
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Currently active medical conditions or ongoing treatments (e.g. irinotecan or any other chemotherapy) that may result in diarrhoea or intermittent loose stools or intractable vomiting during the screening or treatment period.
- •- Evidence of impaired hepatic function (total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), or alkaline phosphatase (AP) >3 times the upper limit of normal, unless known to be due to Gilbert’s syndrome or sickle-cell disease).
- •- Evidence of impaired renal function (glomerular filtration rate [GFR] <60 mL/min/1.73 m2, using the updated bedside Schwartz formula) or subjects with renal failure who are on any form of dialysis.
- •- Any suspected or known physiologic, neurogenic, endocrinic, metabolic, anatomic or other causes of constipation, such as functional constipation, Hirschsprung’s disease, spinal or anal/rectal abnormalities, inflammatory bowel diseases, gastrointestinal perforation or obstruction, other drugs or any gastrointestinal pathology or surgery, likely to significantly influence drug absorption. Faecal impaction at screening.
- •- Pregnancy or breast-feeding.
- •- Any other condition of the subject that, in the opinion of the investigator, may compromise evaluation of the trial treatment or jeopardize subject’s safety, compliance or adherence to protocol requirements.
- •- Administration of any other investigational products, currently or within the last 30 days, unless it is a labelled therapy (adult or paediatric), which is not expected to interfere with the pharmacokinetics/drug absorption of NLX HCl PR tablets.
- •- Employees of the investigator, trial centre, sponsor, CRO and trial consultants, when employees are directly involved in the trial or other studies under the direction of this investigator or trial centre, and their family members.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to investigate the bioavailability of Naloxone in children with opioid induced constipatioEUCTR2015-002310-72-HUDevelco Pharma Schweiz AG72
进行中（未招募）
1 期
Clinical trial to investigate the bioavailability of Naloxone in children with opioid induced constipatioOpioid induced constipationMedDRA version: 20.0Level: LLTClassification code 10071128Term: Opioid induced constipationSystem Organ Class: 100000004856EUCTR2015-002310-72-DEDevelco Pharma Schweiz AG72
进行中（未招募）
1 期
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisGeneralized Myasthenia GravisEUCTR2020-005841-18-Outside-EU/EEAargenx BV
进行中（未招募）
1 期
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersGeneralized Myasthenia GravisEUCTR2020-005841-18-PLargenx BV22
进行中（未招募）
1 期
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersGeneralized Myasthenia GravisEUCTR2020-005841-18-NLargenx BV12